Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04660812 · ClinicalTrials.gov registry record · Phase 1

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

A Phase 1 study of Metastatic Colorectal Cancer, sponsored by Arcus Biosciences.

Completed
Registry status
Phase 1
Development phase
227
Enrollment target
20
Study locations

NCT04660812 is a Phase 1 study of Metastatic Colorectal Cancer that has completed, run by Arcus Biosciences. The registered enrollment target is 227 participants, above the 181-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (25% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04660812, a Phase 1 study of Metastatic Colorectal Cancer, has completed, sponsored by Arcus Biosciences.

COMPLETED
Registry status
Phase 1
Development phase
227 participants
Enrollment target
20
Study locations

Study Summary

This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.

Conditions Studied

Metastatic Colorectal Cancer

Interventions

  • DRUG Bevacizumab
  • DRUG Zimberelimab
  • DRUG Etrumadenant
  • DRUG AB680
  • DRUG m-FOLFOX-6 regimen

Study Locations (20)

Other

  • Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest - Bordeaux
  • Centre Georges Francois Leclerc - Dijon
  • Hopital Hotel Dieu - Nantes

California

  • City of Hope Comprehensive Cancer Center - Duarte
  • UCLA Hematology Oncology - Santa Monica

New York

  • NYU Langone Medical Center - NYU Medical Oncology Associates - New York
  • New York-Presbyterian Hospital-Columbia University Medical Center - New York

Tennessee

  • Vanderbilt-Ingram Cancer Center - Nashville
  • Sarah Cannon Research Institute - Nashville

Arizona

  • Arizona Clinical Research Center Inc - Tucson

Connecticut

  • Yale Cancer Center - New Haven

District of Columbia

  • Sibley Memorial Hospital - Washington D.C.

Georgia

  • Winship Cancer Institute at Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 227 participants
Start Date 2021-05-10
Est. Completion 2025-09-05
Phase Phase 1

Sponsor

Arcus Biosciences

25 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04660812

The ClinicalTrials.gov registry entry for NCT04660812 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 181-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (25% higher). The listed sponsor is Arcus Biosciences, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.

NCT04660812 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, California, New York.

Frequently Asked Questions

What is clinical trial NCT04660812 about?

NCT04660812 is a clinical study titled "An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.". This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.

What is the current status of trial NCT04660812?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 227 participants. The study started on 2021-05-10. Estimated completion is 2025-09-05.

What conditions does trial NCT04660812 study?

This clinical trial studies the following conditions: Metastatic Colorectal Cancer.

What interventions are being tested in trial NCT04660812?

The interventions under investigation include: Bevacizumab (DRUG), Zimberelimab (DRUG), Etrumadenant (DRUG), AB680 (DRUG), m-FOLFOX-6 regimen (DRUG).

Who is sponsoring clinical trial NCT04660812?

This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04660812 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Colorectal Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.